[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stat1-gain-of-function-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stat1-gain-of-function-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":4,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":4,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":14,"phases":4,"briefSummary":15,"conditions":16,"keywords":18,"overallStatus":20,"whyStopped":4,"lastUpdateSubmitDate":21,"lastUpdatePostDateStruct":22,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":25,"locationsCount":4},"100482434",false,"NCT05561985","Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","Expanded access use of Itacitinib to treat a single patient with aplastic anemia.",[17],"STAT1 Gain-of-Function Disease",[19],"STAT1 GOF disease","AVAILABLE","2026-06-09",{"date":23,"type":24},"2026-06-10","ACTUAL",{"name":26,"class":27},"Incyte Corporation","INDUSTRY",""]